Evidence-based recommendations for treatment with methotrexate in rheumatic disorders

Danish Medical Bulletin

Volumn 57, Issue 10, 2010, Pages

  Madsen, Ole Rintek ^a   Faurschou, Mikkel ^b   Loft, Anne Gitte ^c   SØrensen, Inge Juul ^d   Knudsen, John Bonde ^e   Baslund, Bo ^b   Hansen, Annette ^a   Hansen, Michael Sejer ^a   Østergaard, Mikkel ^d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

^d Mental Health Center Glostrup   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DENMARK; EVIDENCE BASED PRACTICE; FEMALE; HEALTH SURVEY; HUMAN; MALE; NORMAL HUMAN; PROFESSIONAL PRACTICE; RATING SCALE; RHEUMATIC DISEASE; RHEUMATOLOGY; DELPHI STUDY; EVIDENCE BASED MEDICINE; INTERNATIONAL COOPERATION; MIDDLE AGED; PATHOLOGY; PRACTICE GUIDELINE; QUESTIONNAIRE; REVIEW;

ADULT; ANTIRHEUMATIC AGENTS; DELPHI TECHNIQUE; DENMARK; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH STATUS INDICATORS; HEALTH SURVEYS; HUMANS; INTERNATIONALITY; MALE; METHOTREXATE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 79251494434     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Pierson DJ. Translating evidence into practice. Respir Care 2009;54:1386-401.
2. Sidiropoulos PI, Hatemi G, Song IH et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 2008;47:355-61.
3. Pedersen SJ, Madsen OR, Erlendsson J et al. Danish recommendations on treatment of ankylosing spondylitis and spondyloarthritis based on multinational project initiative. Ugeskr Læger 2008;170:4044-50.
4. Tarner IH, Müller-Ladner U. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with the focus on rheumatoid arthritis: Integration of a systematic literature research with the expert opinion of a large international panel of rheumatologists within the framework of the 3e initiative. Z Rheumatol 2010;69:250-2.
5. Kain T, Zochling J, Taylor A et al. Evidence-based recommendations for the diagnosis of ankylosing spondylitis: results from the Australian 3E initiative in rheumatology. Med J Aust 2008;188:235-7.
6. D'Angelo S, Padula A, Nigro A et al. Italian evidence-based recommendations for the management of ankylosing spondylitis: the 3E Initiative in Rheumatology. Clin Exp Rheumatol 2008;26:1005-1011.
7. Raptopoulou A, Sidiropoulos P, Siakka P et al. Evidence-based recommendations for the management of ankylosing spondylitis: results of the Hellenic working group of the 3E Initiative in Rheumatology. Clin Exp Rheumatol 2008;26:784-792.
8. Canhão H, Santos MJ, Costa L et al. Portugese recommendations for the use of methotrexate in the treatment of rheumatoid arthritis. Acta Rheumatol Port 2009;34:78-95.
9. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis 2009;68:1086-1093.
10. Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol 2009;21:216-223.
11. Pope JE, Hong P, Koehler BE. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. J Rheumatol 2002;29:255-260.
12. Criswell LA, Henke CJ. What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? J Rheumatol 1995;22:829-835.
13. van Tulder M, Furlan A, Bombardier C et al. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine 2003;28:1290-1299.
14. Shekelle PG, Woolf SH, Eccles M et al. Clinical guidelines: developing guidelines. BMJ 1999;318:593-596.
15. Roddy E, Zhang W, Doherty M et al. Evidence-based clinical guidelines: a new system to better determine true strength of recommendation. J Eval Clin Pract 2006;12:347-352.
16. Furst DE, Koehnke R, Burmeister LF et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16:313-320.
17. Braun J, Kaestner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2008;58:73-81.
18. Katchamart W, Ortiz Z, Shea B et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (an update systematic review and metaanalysis). Arthritis Rheum 2008;58 suppl:S473.
19. Maetzel A, Wong A, Strand V et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000;39:975-81.
20. Katchamart W, Trudeau J, Phumethum V et al. The efficacy and toxicity of methotrexate (MTX) monotherapy vs MTX combination therapy with non-biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and metaanalysis. Ann Rheum Dis 2009;68:1105-12.